AI assistant
Athira Pharma, Inc. — Director's Dealing 2022
Jun 10, 2022
35038_dirs_2022-06-10_db26d4c1-90c0-43a0-aa6b-f6c9a9b84ddb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-06-08
Reporting Person: CHURCH KEVIN (Executive VP, Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-18 | Common Stock | A | 243 | $7.06 | Acquired | 47809 | Direct |
| 2022-06-08 | Common Stock | M | 2500 | $1.35 | Acquired | 50309 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-08 | Stock Option (Right to Buy) | $1.35 | M | 2500 | Disposed | 2028-12-17 | Common Stock (2500) | Direct |
Footnotes
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).
F2: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.
F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.
F4: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.